Oral voriconazole for empiric antifungal treatment in patients with uncomplicated febrile neutropenia

Pharmacotherapy

Volumn 28, Issue 1, 2008, Pages 58-63

  Przepiorka, Donna ^a   Buadi, Francis K ^a   McClune, Brian ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Antifungal antibiotic; Empiric antifungal treatment; Neutropenic fever; Uncomplicated febrile neutropenia; Voriconazole

Indexed keywords

ACICLOVIR; AMPHOTERICIN; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE; LEVOFLOXACIN; MICAFUNGIN; POSACONAZOLE; VALACICLOVIR; VORICONAZOLE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC PROPHYLAXIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER PATIENT; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DRUG COST; DRUG SAFETY; FEBRILE NEUTROPENIA; HUMAN; INFECTION; KIDNEY FUNCTION; LABORATORY TEST; LEUKOCYTE COUNT; LIVER FUNCTION; MYCOSIS; PHOTOPHOBIA; RASH; RETROSPECTIVE STUDY; SIDE EFFECT; SURVIVAL RATE; TREATMENT OUTCOME; VISUAL DISORDER;

ADMINISTRATION, ORAL; ADULT; AGED; ALANINE TRANSAMINASE; ANTIFUNGAL AGENTS; ASPARTATE AMINOTRANSFERASES; BILIRUBIN; CREATININE; EXANTHEMA; FEMALE; FEVER; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; MYCOSES; NEUTROPENIA; PYRIMIDINES; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; TRIAZOLES;

EID: 38049014448     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.28.1.58     Document Type: Article

References (22)

1. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730-51.
2. Bow EJ, Laverdiere M, Lussier N, Rotstein C, Cheang MS, Ioannou S. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials. Cancer 2002;94:3230-46.
3. Martino R, Viscoli C. Empirical antifungal therapy in patients with neutropenia and persistent or recurrent fever of unknown origin. Br J Haematol 2005;132:138-54.
4. Kappe R. Antifungal activity of the new azole UK-109, 496 (voriconazole). Mycoses 1999;42(suppl 2):83-6.
5. Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002;346:225-34.
6. Purkins L, Wood N, Ghahramani P, Greenhalgh K, Allen MJ, Kleinermans D. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother 2002;46:2546-53.
7. Purkins L, Wood N, Greenhalgh K, Allen MJ, Oliver SD. Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety. Br J Clin Pharmacol 2003;56(suppl 1):10-16.
8. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002;34:7-14.
9. Prentice HG, Hann IM, Herbrecht R, et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 1997;98:711-18.
10. White MH, Bowden RA, Sandler ES, et al. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis 1998;27:296-302.
11. Malik IA, Moid I, Aziz Z, Khan S, Suleman M. A randomized comparison of fluconazole with amphotericin B as empiric antifungal agents in cancer patients with prolonged fever and neutropenia. Am J Med 1998;105:478-83.
12. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 1999;340:764-71.
13. Winston DJ, Hathorn JW, Schuster MG, Schiller GJ, Territo MC. A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. Am J Med 2000;108:282-9.
14. Boogaerts M, Winston DJ, Bow EJ, et al. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy: a randomized, controlled trial. Ann Intern Med 2001;135:412-22.
15. Subira M, Martino R, Gomez L, Marti JM, Estany C, Sierra J. Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies: a randomized, controlled trial. Eur J Haematol 2004;72:342-7.
16. Wingard JR, White MH, Anaissie E, Raffalli J, Goodman J, Arrieta A. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clin Infect Dis 2000;31:1155-63.
17. Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004;351:1391-402.
18. Yanada M, Kiyoi H, Murata M, et al. Micafungin, a novel antifungal agent, as empirical therapy in acute leukemia patients with febrile neutropenia. Intern Med 2006;45:259-64.
19. Stemmer SM, Maor Y, Hardan I. Oral fluconazole for empiric treatment of prolonged fever in neutropenic patients: prospective study in 250 consecutive patients after stem cell transplantation. Am J Clin Oncol 2004;27:328-32.
20. Ullmann AJ, Cornely OA, Burchardt A, et al. Pharmacokinetics, safety and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother 2006:50:658-66.
21. Prentice HG, Kibbler CC, Prentice AG. Towards a targeted, risk-based, antifungal strategy in neutropenic patients. Br J Haematol 2000;110:273-84.
22. Pfizer, Inc. Vfend (voriconazole) package insert. New York, NY; 2006.